TAKE Solutions, MENE Research tie-up to capture emerging pharma mkts globally

Image
Announcement Corporate
Last Updated : Jan 21 2013 | 12:53 AM IST

TAKE - MENE partnership to offer a wide range of strategic solutions and services catering to the growing needs for Drug Safety Solutions in Pharma Emerging Nations

TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leader in the Life Sciences solutions development, has strengthened its Drug Safety & Pharmacovigilance solutions and services offering to cater to the growing needs of Pharma Emerging nations. The Company has partnered with MENE Research wherein they together will cater to the Drug Safety requirements of Middle East, Europe and West Asian countries.

“We are extremely pleased to partner with MENE Research and are sure that our expertise and global presence will help us to further explore the emerging Pharma markets. We will ensure that clients benefit from highly efficient, proactive and affordable solutions and services to meet global pharmacovigilance needs of sponsor companies, affiliates and agencies. Our engagement with MENE is evidence of TAKE Solutions’ comprehensive understanding of the business, the challenges and proven track record of providing intelligent and innovative drug safety operations and pharmacovigilance solutions,” said, Prashanth Visweswaran, Director - Drug Safety Practice, TAKE Solutions.

Sule Mene, CEO, MENE Research says “When we started talks with TAKE Solutions our main criteria was an entity that offered Pharmacovigilance solutions & services which was in compliance with applicable current regulatory and privacy directives and they completely fulfilled our requirements. TAKE has a deep understanding of how to translate customer’s drug safety requirements into specific process steps which ensure compliance and proactive analysis thereby improving patient safety. All these factors made us believe that they will be the most beneficial partners in our endeavor to provide Pharma companies Pharmacovigilance services globally.”

Both the companies together will work towards providing the life science industry with strategy, solutions and services for drug safety operations thus ensuring global regulatory compliance and effective patient safety methodologies is followed. This partnership becomes strong by the fact that TAKE already has to its credit creating a framework - SafetyReady™ along with a thought leadership in Drug Safety and Pharmacovigilance segments and Mene Research’s regional expertise in Middle East, Europe, West Asia etc.

TAKE Solutions extended Drug Safety & Pharmacovigilance Service Offerings with recent launch of SafetyReady for Oracle Argus Safety Suite Customers.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 15 2011 | 3:35 PM IST

Next Story